Nicox is a biopharmaceutical company based in Sophia Antipolis, France, focused on developing and commercializing nitric oxide (NO)-donating drugs for various health conditions, particularly inflammation and cardio-metabolic diseases. The company's primary product candidates include Naproxcinod, which is in Phase III trials for osteoarthritis, and NCX 6560, an NO-donating compound in Phase I trials targeting cardiovascular diseases. Additionally, Nicox's portfolio features several drugs in clinical development, such as PF-03187207 for glaucoma, TPI 1020 for respiratory disorders, and NCX 1510 for allergic rhinitis, all in Phase II trials. The company's pipeline also includes NCX 1047, aimed at treating skin disorders, and various NO-donors for conditions like diabetic retinopathy and hypertension. Collaborations with organizations such as Orexo AB, Pfizer Inc., and Merck & Co. further enhance its research and development capabilities. Founded in 1996, Nicox is dedicated to advancing innovative therapeutic solutions to improve patient outcomes in ophthalmology and beyond.
Doliage specializes in ophthalmic products, focusing on medical food supplements and pharmaceuticals designed to address various eye conditions. Established in 2004, the company was among the first to develop a supplement specifically for ophthalmology, incorporating the latest scientific research into their formulations. Doliage gained recognition for being the first to combine lutein and omega-3 fatty acids in 2005, a formulation that has since become standard in the field of micronutrition for eye health. Additionally, since 2009, the company's products have included B vitamins, further enhancing their offerings. Doliage's pharmaceutical portfolio includes prescription medications for conditions such as dry eye syndrome, glaucoma, and eye infections, including Euronac, which aids in corneal healing, and Tobrabact Ge, an ocular antibiotic. All Doliage products are manufactured in a controlled pharmaceutical environment to ensure the highest quality standards.
Aciex Therapeutics
Acquisition in 2014
Aciex is focused on developing first-in-class products to fill unmet needs for ophthalmic therapeutics—products that will permit us to build a sustainable ophthalmic franchise. They believe their company is unique in both concept and products and timely in terms of the market, and they are pleased you have chosen to learn more about Aciex.
EuPharmed
Acquisition in 2013
EuPharmed s.r.l. is a pharmaceutical company that focuses on the development and marketing of products within the ophthalmological sector. The company offers a range of pharmaceutical products, over-the-counter items, parapharmaceuticals, nutraceuticals, and medical devices. Its portfolio is designed to address various ocular pathologies and ophthalmic diseases, positioning EuPharmed as a key player in the healthcare market for eye-related conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.